Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma
Authors:
- 6 January 2022
- journal article
- research article
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 407 (3) , 965-974
Abstract
Purpose Neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC) in Japan. Computed tomography (CT) is usually used to assess the therapeutic effect of NAC; however, there are no reliable criteria for predicting pathological response or patient prognosis. Methods We included 84 patients who underwent esophagectomy between January 2009 and December 2018 and retrospectively reviewed their CT scans performed before and after NAC. The reduction rate of the largest tumor area (TA), long diameter (LD), and short diameter (SD) were measured on a transverse CT image. The pathological response and cutoff values were calculated using the receiver operating characteristic curve, and the most suitable ones for determining the effect were examined. Results The areas under the curve for predicting responders to NAC based on the reduction rate of the TA, LD, and SD were 0.755, 0.761, and 0.781, respectively. The optimal cutoff value of the SD reduction rate for predicting responders to NAC was 22%. An SD reduction ≥ 22% was an independent prognostic factor for overall survival in univariate (p = 0.005, hazard ratio [HR] = 2.755) and multivariate analyses (p = 0.030 HR 2.690). Furthermore, an SD reduction of ≥ 22% was also an independent prognostic factor for relapse-free survival in the univariate (p = 0.007, HR = 2.491) and multivariate analyses (p = 0.007, HR = 0.030). Conclusions The reduction rate of the tumor SD is a simple predictor of pathological response and patient prognosis.Keywords
This publication has 26 references indexed in Scilit:
- Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinomaCancer Science, 2013
- Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapyDiseases of the Esophagus, 2013
- Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancerEuropean Radiology, 2013
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinomaEuropean Journal of Cardio-Thoracic Surgery, 2012
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- Worldwide esophageal cancer collaborationDiseases of the Esophagus, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Use of 18F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinomaSurgery, 2008
- Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal CancerThe Annals of Thoracic Surgery, 2004